Pluristem Therapeutics Inc. announced that the results of the company's Phase I/II clinical trial testing the safety and efficacy of PLacental Expanded (PLX-PAD) cells for the treatment of muscle injury will be presented on January 21, 2014. The Principal Investigator of the study will join Pluristem's management to discuss these results as part of Pluristem's Regenerative Medicine Day to be held on January 21, 2014 at the Tel Aviv Stock Exchange, Tel Aviv Israel. This randomized, placebo-controlled, double blinded study was conducted at the Orthopedic Clinic on the campus of the Charité University Medical School under the auspices of the Paul-Ehrlich-Institute (PEI), Germany's health authority.

The injured muscle studied was the gluteal buttock muscle that has been surgically traumatized during total hip replacement surgery. The study was comprised of 3 treatment groups, two PLX-PAD groups of different doses and one placebo group. The primary endpoints of the study include safety and the maximal contraction force of the gluteal muscle at six months post-surgery.

The secondary efficacy endpoints include an analysis of the macrostructure and microstructure of the gluteal muscle using magnetic resonance imaging (MRI) and biopsy.